Entering text into the input field will update the search result below

IN8bio wins FDA Orphan Drug designation for glioma candidates

Apr. 25, 2023 9:02 AM ETIN8bio, Inc. (INAB)By: Jonathan Block, SA News Editor1 Comment

Brain cancer, showing presence of tumor inside brain. 3d illustration

Mohammed Haneefa Nizamudeen/iStock via Getty Images

  • The US FDA has granted Orphan Drug designation to IN8bio's (NASDAQ:INAB) INB-400 and INB-410 to treat several types of glioma.
  • Both are gamma-delta T cell therapies intended to initially treat glioblastoma multiform, a type of brain cancer.
  • Patient enrollment in a phase 2 trial for INB-400 is set to begin in the second half of the year.
  • Despite the positive news, IN8bio shares are down 10% in premarket trading Tuesday.
  • On Monday, IN8bio (INAB) rose more than 100% on data from a phase 1 trial of INB-100 in patients with leukemia

Recommended For You

Comments (1)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.